Insmed INC 10-Q quarterly reports

Insmed Incorporated's Q2 2026 Form 10-Q filing reveals a substantial increase in product revenues, primarily due to the commercial launch of BRINSUPRI, alongside continued investment in research and development.

Insmed Incorporated announced a significant increase in total product revenues for the first quarter of 2026, primarily driven by the successful launch of Brensubri in the US, alongside continued growth in ARIKAYCE international sales.

Insmed Incorporated reports significant revenue growth in Q3 2025, driven by the US launch of BRINSUPRI and continued ARIKAYCE sales, despite increased operating losses due to substantial R&D and commercialization investments.

Insmed Incorporated reported significant revenue growth for ARIKAYCE and positive clinical trial results for brensocatib and TPIP, while continuing to incur substantial operating losses.

Insmed Incorporated's Q1 2025 results show increased ARIKAYCE sales and progress in the development of brensocatib, with a potential US launch anticipated in Q3 2025.

Insmed's Q3 2024 results show revenue growth driven by ARIKAYCE sales, alongside continued progress in clinical development programs.

Insmed's second quarter 2024 results show increased revenue and a net loss, alongside significant clinical trial advancements and strategic financial activities.

Insmed's Q1 2024 results show a 15.8% increase in product revenue driven by ARIKAYCE sales, alongside updates on clinical programs and financial performance.